胰高血糖素样肽-1类似物联合二甲双胍治疗对2型糖尿病胰岛功能及体脂率的影响

Efficacy of human glucagon-like peptide-1 analogue combined with metformin on pancreatic islet Function and body fat ratio of patients with type 2 diabetes

目的探讨胰高血糖素样肽-1类似物利拉鲁肽联合二甲双胍治疗对2型糖尿病胰岛功能及体脂率的影响。方法纳入30例2型糖尿病患者,在给予二甲双胍治疗的基础上联合利拉鲁肽治疗26周,分别在治疗4周和26周时随访比较血糖、胰岛功能及体脂率变化情况。结果治疗4周时患者空腹血糖和糖化血红蛋白(Hb A1c)较治疗前明显降低(P<0.05),在治疗26周时,空腹血糖、标准餐后2h血糖、Hb A1c、体重和体脂率较治疗前均显著降低(P<0.05),反映胰岛β细胞功能的胰岛素分泌指数(HOMA-B)明显升高(P<0.05)。结论利拉鲁肽联合二甲双胍治疗2型糖尿病能够有效控制血糖、减轻体重、减少体内脂肪、改善胰岛β细胞功能,同时具有良好的安全性,在临床工作中合并肥胖的2型糖尿病患者尤其适合选用该方案进行治疗。

Objective To investigate the efficacy of the human glucagon - like peptide - 1 analogue liraglutide combined with metformin on pancreatic islet function and body fat ratio of patients with type 2 Diabetes. Methods Totally 30 cases of type 2 diabetes were inrolled, on tbe basis of mefformin given liraglutide 0. 6mg once daily for 4weeks, then 1.2mg for 22 weeks, followed up at 4 and 26 weeks. Results After 4 weeks of liraglutide and mefformin treatment, fasting glucose and HbA1 c was significantly lower than before （P 〈 0. 05 ）. After 24weeks treatment, were associated with significantly lower in fasting glucose, 2 -hour postprandial glucose, HbA1c, body weight and body fat ratio （P 〈 0. 05）. The insulin secretion index （ HOMA - B） was significantly increased （ P 〈 0.05 ）. Conclusion Treatment of liraglutide combined with metformin effectively improved glucose control and islet β-cell function, reduced weight and body fat retio.